Artivion, Inc. (AORT)
NYSE: AORT · Real-Time Price · USD
28.75
+0.04 (0.14%)
Jun 3, 2025, 1:43 PM - Market open

Company Description

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.

The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products.

It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.

In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers.

It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.

The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022.

Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion, Inc.
Artivion logo
Country United States
Founded 1984
IPO Date Feb 11, 1993
Industry Medical Devices
Sector Healthcare
Employees 1,600
CEO James Mackin

Contact Details

Address:
1655 Roberts Boulevard NW
Kennesaw, Georgia 30144
United States
Phone 770 419 3355
Website artivion.com

Stock Details

Ticker Symbol AORT
Exchange NYSE
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000784199
CUSIP Number 228903100
ISIN Number US2289031005
Employer ID 59-2417093
SIC Code 3841

Key Executives

Name Position
James Patrick Mackin Chairman, President and Chief Executive Officer
Lance A. Berry CPA Executive Vice President of Finance and Chief Financial Officer
Jean F. Holloway Esq. Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
John E. Davis Senior Vice President and Chief Commercial Officer
Dr. Marshall S. Stanton M.D. Senior Vice President of Clinical Research and Chief Medical Officer
Florian Tyrs Vice President of Global Operations
Amy D. Horton CPA Vice President and Chief Accounting Officer
Matthew A. Getz Vice President of Human Resources and Chief Human Resources Officer
Dr. Robert C. Thomson Ph.D. Vice President of Research and Development

Latest SEC Filings

Date Type Title
May 29, 2025 8-K Current Report
May 27, 2025 144 Filing
May 23, 2025 144 Filing
May 21, 2025 144 Filing
May 21, 2025 144 Filing
May 19, 2025 SD Form - SD
May 16, 2025 8-K Current Report
May 14, 2025 8-K Current Report
May 12, 2025 SCHEDULE 13G Filing
May 9, 2025 144 Filing